David Kronn is a Rare/Genetic physician affiliated with New York Medical College. OpenAlex indexes 80 publications with 2,716 citations (h-index 23).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
503 Grasslands Rd
Ste 200
Valhalla, NY 105951503
Telephone
914-304-5280Provider last certified this registry record 21 May 2021.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20254 payments
- Amicus Therapeutics, Inc.Program year20252 payments
- GENZYME CORPORATIONProgram year202421 payments$25,843openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Phenylalanine Hydroxylase Activator64.5%Sapropterin Dihydrochloride100%Part D<11 patientsCarnitine Analog17.4%Levocarnitine100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry
Orphanet Journal of Rare Diseases
2023 - P687: State of play: The current landscape of newborn screening for Pompe disease in the United States
Genetics in Medicine Open
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Mitchell Cairo, MD
New York Medical College
Leslie Citrome, MD, MPH
New York Medical College
Jerry Nadler
New York Medical College
Karen Seiter, MD
New York Medical College
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”